KR20230052963A - Fgfr3 항체 및 사용 방법 - Google Patents

Fgfr3 항체 및 사용 방법 Download PDF

Info

Publication number
KR20230052963A
KR20230052963A KR1020237009493A KR20237009493A KR20230052963A KR 20230052963 A KR20230052963 A KR 20230052963A KR 1020237009493 A KR1020237009493 A KR 1020237009493A KR 20237009493 A KR20237009493 A KR 20237009493A KR 20230052963 A KR20230052963 A KR 20230052963A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009493A
Other languages
English (en)
Korean (ko)
Inventor
이브 사바그
양데 첸
윌리엄 브론디크
화웨이 치우
성해 박
론니 웨이
유 치우
얀펭 조우
센드린 르모인
현석 조
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20230052963A publication Critical patent/KR20230052963A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237009493A 2020-08-21 2021-08-20 Fgfr3 항체 및 사용 방법 Pending KR20230052963A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068575P 2020-08-21 2020-08-21
US63/068,575 2020-08-21
PCT/US2021/046958 WO2022040560A1 (en) 2020-08-21 2021-08-20 Fgfr3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
KR20230052963A true KR20230052963A (ko) 2023-04-20

Family

ID=77774991

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009493A Pending KR20230052963A (ko) 2020-08-21 2021-08-20 Fgfr3 항체 및 사용 방법

Country Status (14)

Country Link
US (2) US11505611B2 (https=)
EP (1) EP4200019A1 (https=)
JP (1) JP2023538098A (https=)
KR (1) KR20230052963A (https=)
CN (1) CN116323666A (https=)
AR (1) AR123306A1 (https=)
AU (1) AU2021327387A1 (https=)
BR (1) BR112023002455A2 (https=)
CA (1) CA3189470A1 (https=)
CO (1) CO2023001559A2 (https=)
IL (1) IL300623A (https=)
MX (1) MX2023002106A (https=)
TW (1) TW202229343A (https=)
WO (1) WO2022040560A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2023379451A1 (en) * 2022-11-14 2025-05-01 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
KR20250148746A (ko) 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2025207944A1 (en) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Fgfr3-iiib-binding antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215581B (hu) 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
WO1994000599A2 (en) 1992-06-18 1994-01-06 Whittier Institute For Diabetes And Endocrinology Process for detection of neoplastic disease
AU6446194A (en) 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
AU5214500A (en) 1999-05-05 2000-11-21 Centre National De La Recherche Scientifique (C.N.R.S.) Means for detecting and treating pathologies linked to fgfr3
DE20023659U1 (de) 1999-10-06 2005-07-07 Tigenix N.V. Molekulare Marker zum Testen der phänotypischen Stabilität von Zellpopulationen und Zellpopulationen für die autologe Transplantation
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1469878B1 (en) 2002-01-31 2011-03-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
WO2004003179A1 (en) 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
WO2004022095A1 (en) 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
JP2007524566A (ja) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
EP1611252B1 (en) 2003-03-26 2009-07-29 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP1544213B1 (en) 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
EP1697420A2 (en) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
AU2005302083A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009511613A (ja) 2005-10-17 2009-03-19 エンカム ファーマシューティカルズ アクティーゼルスカブ 神経細胞接着分子ｌ１のペプチド断片を含む新規ｆｇｆ受容体結合化合物
KR20080080525A (ko) 2005-12-08 2008-09-04 노파르티스 아게 유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008127707A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
PL2824181T3 (pl) 2012-03-08 2019-02-28 Astellas Pharma Inc. Nowa fuzja fgfr3
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20150292030A1 (en) 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
WO2014161075A1 (en) 2013-04-05 2014-10-09 University Health Network Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
BR112017017700A2 (pt) 2015-02-19 2018-07-31 Bioclin Therapeutics Inc métodos, composições e kits para tratamento do câncer
SG11201906249PA (en) 2017-02-06 2019-08-27 Rainier Therapeutics Inc Methods, compositions, and kits for treatment of cancer

Also Published As

Publication number Publication date
US20230303704A1 (en) 2023-09-28
BR112023002455A2 (pt) 2023-03-28
EP4200019A1 (en) 2023-06-28
IL300623A (en) 2023-04-01
AR123306A1 (es) 2022-11-16
AU2021327387A1 (en) 2023-05-04
MX2023002106A (es) 2023-03-15
US20220056142A1 (en) 2022-02-24
CO2023001559A2 (es) 2023-02-16
AU2021327387A9 (en) 2023-07-06
WO2022040560A1 (en) 2022-02-24
TW202229343A (zh) 2022-08-01
CN116323666A (zh) 2023-06-23
US11505611B2 (en) 2022-11-22
JP2023538098A (ja) 2023-09-06
CA3189470A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7610302B2 (ja) Ｃｃｒ８抗体及びその用途
TWI803523B (zh) Ｔｉｇｉｔ抗體、其抗原結合片段及醫藥用途
US11505611B2 (en) FGFR3 antibodies and methods of use
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
US20220281965A1 (en) Antibodies directed against gdf-15
US20250145705A1 (en) Gprc5d antibody and application thereof
CN110099924A (zh) Gremlin-1晶体结构和抑制性抗体
US20230406922A1 (en) Humanized cd19 antibody and use thereof
JP2021515542A (ja) Ｐｄ１結合剤
JP2022518062A (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
CN116323664A (zh) 抗β细胞素抗体、其片段和多特异性结合分子
TW201922798A (zh) 靶向rankl的治療性抗體
KR20240126872A (ko) TrkA 항체 및 이의 응용
TW202334220A (zh) 人類腫瘤壞死因子α抗體
TWI918704B (zh) Ｃｃｒ８抗體及其應用
US20250277038A1 (en) Anti-pd-l1 antibody and use thereof
KR20260047589A (ko) Btn3a 결합 단백질 및 이의 의학적 용도
JP2024544386A (ja) Ｐｄ－ｌ１抗原結合タンパク質及びその使用
JP2026506623A (ja) 抗ｃｄｈ６抗体及びその使用
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240820

Comment text: Request for Examination of Application